Catalytic enantioselective conjugate addition of dialkylzinc reagents to N-substituted-2,3-dehydro-4-piperidones
作者:Radovan Šebesta、Maria Gabriella Pizzuti、Arnold J. Boersma、Adriaan J. Minnaard、Ben L. Feringa
DOI:10.1039/b417727d
日期:——
The first, highlyenantioselective, copper/phosphoramidite-catalyzed conjugateaddition of dialkylzinc reagents to N-substituted 2,3-dehydro-4-piperidones is described.
Multinuclear Catalyst for Copper-Catalyzed Asymmetric Conjugate Addition of Organozinc Reagents
作者:Kohei Endo、Mika Ogawa、Takanori Shibata
DOI:10.1002/anie.200906839
日期:2010.3.22
A whole lot o' metal: An efficient copper‐catalyzed asymmetric conjugate addition was achieved using a binol‐derived ligand. The catalytic system has a turnover number of 2000, and the excellent catalytic performance could be attributed to the generation of a multinuclear complex such as 1. binol=2,2′‐dihydroxy‐1,1′‐binaphthyl.
Copper-Catalyzed Asymmetric 1,4-Addition of Alkenyl Alanes to <i>N</i>-Substituted-2-3-dehydro-4-piperidones
作者:Daniel Müller、Alexandre Alexakis
DOI:10.1021/ol3004436
日期:2012.4.6
Readily available vinyl alanes are used in the Cu-catalyzed asymmetric conjugate addition reaction to N-substituted-2-3-dehydro-4-piperidones. The enhanced reactivity of recently developed and easily prepared phosphine amine ligands in combination with inexpensive Cu(II)naphtenate (CuNp) allows the introduction of a great variety of alkenyl, alkyl, and aryl aluminums in high enantioselectivity.
Ferrocene phosphane–carbene ligands in Cu-catalyzed enantioselective 1,4-additions of Grignard reagents to α,β-unsaturated carbonyl compounds
Chiral ferrocene phosphane-carbenes are good ligands for the copper-catalyzed 1,4-addition of Grignard reagents to various Michael acceptors. The products were obtained in high enantiomeric purity (up to e.r. = 95:5) and excellent regioselectivity (r.r. = 99:1). These ligands are also useful for domino conjugate addition followed by enolate trapping with imine and aldehyde. (C) 2013 Elsevier B.V. All rights reserved.
NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION